Skip to main content
SpringerLink
Log in

Selegiline-Transdermal — Somerset

Emsam

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Farlow MR, Tariot P, Hochadel T, Hake HM, Schneider L. Disease stage severity at baseline influenced by progression rate in a 48-week selegiline Alzheimer’s disease treatment trial. Neurology 52 (Suppl 2): 172–173 (& oral presentation), 12 Apr 1999

    Google Scholar 

  2. Blob LF, Sharoky M. Safety and efficacy of the selegiline transdermal system for ADHD. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry: 93, 22 Oct 2002

    Google Scholar 

  3. Hauser RA, Stern MB, Olanow CW, et al. Tolerability and safety of transdermal selegiline monotherapy in mild to moderate Parkinson’s disease. Movement Disorders 13 (Suppl 2): 256, 1998

    Google Scholar 

  4. McLean Hospital. McLean Hospital testing skin patch for depression. Media Release: [2 pages], 7 Oct 1998. Available from URL: http://www.mcleanhospital.org

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Selegiline-Transdermal — Somerset. Drugs in R&D 4, 59–60 (2003). https://doi.org/10.2165/00126839-200304010-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304010-00012

Keywords

Search

Navigation